Cure My Disease

Don't miss your cure!

 Log in / Sign up

First patients test new 'Double-Target' cancer drug

NCT ID NCT04540796

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

Summary

This was the first human study of a new experimental drug called JNJ-75348780 for people with advanced non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or stopped responding to other treatments. The main goals were to find a safe dose and understand the drug's side effects in 147 participants. The drug is designed to work by attaching to both cancer cells and the body's immune cells, aiming to direct the immune system to attack the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Austin Hospital

    Heidelberg, 3084, Australia

  • CHRU de Lille Hopital Claude Huriez

    Lille, 59037, France

  • CHU Nantes

    Nantes, 44093, France

  • Carmel Medical Center

    Haifa, 34362, Israel

  • Centre hospitalier Lyon-Sud

    Pierre-Bénite, 69495, France

  • Chang-Gung Memorial Hospital, Kaohsiung

    Kaohsiung City, 83301, Taiwan

  • China Medical University Hospital

    Taichung, 40402, Taiwan

  • Clinica Univ. de Navarra

    Pamplona, 31008, Spain

  • Hadassah Medical Center

    Jerusalem, 9112001, Israel

  • Hosp Clinico Univ de Salamanca

    Salamanca, 37007, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, 28040, Spain

  • Hosp. Univ. Germans Trias I Pujol

    Barcelona, 8916, Spain

  • Hospital de Vall D'Hebron

    Barcelona, 08035, Spain

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Kings College Hospital

    London, SE5 9RS, United Kingdom

  • Leicester Royal Infirmary

    Leicester, LE1 5WW, United Kingdom

  • Linear Clinical Research Ltd

    Nedlands, 6009, Australia

  • National Cheng Kung University Hospital

    Tainan, 70403, Taiwan

  • National Taiwan University Hospital

    Taipei, 10048, Taiwan

  • Plymouth Hospital NHS Trust

    Plymouth, PL6 8DH, United Kingdom

  • Rambam Medical Center

    Haifa, 31096, Israel

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, 03722, South Korea

  • Sheba Medical Center

    Ramat Gan, 74047, Israel

  • Taichung Veterans General Hospital

    Taichung, 40705, Taiwan

  • Tel Aviv Sourasky MC

    Tel Aviv, 6423906, Israel

  • The Catholic University of Korea Seoul St Marys Hospital

    Seoul, 06591, South Korea

  • The Christie Nhs Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

Conditions

Explore the condition pages connected to this study.

LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL LYMPHOMA, NON-HODGKIN